Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What’s Next? Five Things To Look Out For In March

Bristol Myers Squibb Braces For US Impact To Revlimid And Abraxane

Executive Summary

This month, generic competition to several lucrative brands, not least Bristol Myers Squibb’s $8.7bn Revlimid, are set to fall to generic competition in the US. Meanwhile, Sawai is looking to close on a key deal.

You may also be interested in...



Revlimid Rivals Launch Across Europe

Generic versions of Revlimid have been launched in countries across Europe, with Sandoz and Stada among those to have confirmed the introduction of lenalidomide in numerous European markets. Meanwhile, US competition to Revlimid is expected next month.

Sprycel And Vidaza Generics Among Five First-Times For Sawai

Fresh from announcing a major deal that will see it take over a network of facilities, Japanese player Sawai says its aim is to “further increase production by strengthening the personnel structure.”

Cipla Remains Upbeat On Abraxane As US Generic Competition Looms

Cipla has provided the latest on its US complex pipeline ahead of several potential launches in the firm’s upcoming 2022/23 financial year. The Indian firm enjoyed 6% group revenue growth in Q3 FY2022 and is on track to hit its EBITDA margin target.

Related Content

Topics

UsernamePublicRestriction

Register

GB151691

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel